
    
      1. Dopamine agonist can delay the risk of dyskinesia by initiating treatment rather than
           levodopa. Amantadine is typical antidyskinetic drug. There is no data about comparison
           of risk of dyskinesia in amantadine and dopamine agonist by initiating treatment.

        2. Prospective , randomized, open label study compare the onset time and severity of
           dyskinesia between groups randomized assigned order of amantadine and dopamine agonist
    
  